



Financé
par



GOUVERNEMENT

*Liberté
Égalité
Fraternité*



Financé par
l'Union européenne
NextGenerationEU



May 19th, 2022 in Nantes-Saint Herblain, France: Naogen Pharma appoints Nicolas Cherrier as Managing Director and continues the development of the GO Radiopharma project.

Nantes-Saint Herblain, France, May 19th, 2022 - Naogen Pharma, a winner of the government recovery plan (GO Radiopharma project), developing an innovative radiopharmaceutical molecular imaging solution to assess regional myocardial perfusion in adult patients with known or suspected coronary artery disease, announced today the appointment of Nicolas Cherrier as Managing Director.

Nicolas' arrival at the head of Naogen Pharma's radiopharmaceutical and commercial operations will strengthen the management team, which is already strong in experienced profiles. This restructured team will allow Naogen Pharma to finalize its development, to obtain its first MA (Marketing Authorization) and to prepare for the commercialization planned for 2023.

"I am honored to lead the operations of Naogen Pharma with our passionate, experienced and complementary team," said Nicolas Cherrier. "Naogen Pharma's approach to excellence and its industrial and R&D program to promote PET-Rubidium imaging is unique in Europe."

Naogen Pharma builds on the research work conducted as part of the Quanticardi project launched in 2012, in partnership with GIP Arronax, under the leadership of Jean-François Chatal, Professor Emeritus in Nuclear Medicine and Pierre-Marie Lemer, CEO of Lemer Pax, which developed and produces the RUBIJET, the injector that allows Rubidium-82 chloride to be injected into the patient to perform myocardial PET imaging (Positron Emission Tomography). Rubidium-82 (daughter nuclide) is produced from the decay of Strontium-82 (father nuclide), after elution from the column of the radiopharmaceutical generator, the RUBIGEN. This product was developed and is produced under GMP conditions by Naogen Pharma at its pharmaceutical production site in Saint Herblain.

"We are delighted to have Nicolas take over the lead of Naogen Pharma's operations and to welcome him to the strategic committee," said Sylvain Fanier, President of Naogen Pharma. "His experience, his global network in radiopharmaceuticals, and his personality will ensure the success of our late-stage development and commercialization.

Sebastien Avila, who has led Naogen Pharma's R&D operations since the Quanticardi project, joined Naogen as CTO at its creation in 2016. With his experience in industrial developments in nuclear medicine (AAA-Novartis, Arronax, Lemer Pax, Naogen Pharma), Sébastien takes the leadership of the "GO Radiopharma Industry" project, as Project Manager, in the dynamics of the governmental recovery plan, in order to implement a new radiopharmaceutical production unit in Saint Herblain.

Chantal Krezel, who has implemented the Quality Management System (QMS) since her arrival in 2019, is appointed "GO Radiopharma Clinical Project Manager". With her experience in clinical research, Chantal will lead, with Jean-François Chatal, founder and Medical Director, the clinical development projects.

About NAOGEN PHARMA

NAOGEN PHARMA, a radiopharmaceutical laboratory, develops and produces non-invasive PET (Positron Emission Tomography) molecular imaging solutions for hospital nuclear medicine departments. NAOGEN PHARMA uses an innovative nuclide used in PET imaging, Rubidium-82 (Rb-82). From the world-class nuclear medicine cluster in Nantes, NAOGEN PHARMA and its partners are committed to the worldwide development of Rubidium-82 PET imaging.

For more information, visit www.naogen-pharma.com